CINECA IRIS Institutional Research Information System

ARVAT, Emanuela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.112
EU - Europa 8.871
AS - Asia 6.194
SA - Sud America 126
AF - Africa 68
OC - Oceania 53
Continente sconosciuto - Info sul continente non disponibili 13
Totale 27.437
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.770
CN - Cina 4.159
IT - Italia 1.293
IE - Irlanda 1.263
SE - Svezia 1.210
UA - Ucraina 1.190
DE - Germania 958
FR - Francia 821
FI - Finlandia 669
SG - Singapore 643
KR - Corea 642
GB - Regno Unito 506
CA - Canada 322
PL - Polonia 292
VN - Vietnam 225
AT - Austria 173
JP - Giappone 135
RU - Federazione Russa 135
NL - Olanda 88
IN - India 86
PH - Filippine 66
BE - Belgio 62
BR - Brasile 55
TR - Turchia 49
AU - Australia 46
GR - Grecia 46
ES - Italia 43
UZ - Uzbekistan 41
HK - Hong Kong 38
AR - Argentina 33
MU - Mauritius 28
TW - Taiwan 24
DK - Danimarca 22
IR - Iran 21
CH - Svizzera 16
EU - Europa 12
PT - Portogallo 11
RO - Romania 11
ZA - Sudafrica 11
CO - Colombia 10
SA - Arabia Saudita 10
CL - Cile 9
HU - Ungheria 9
CR - Costa Rica 8
CZ - Repubblica Ceca 8
HR - Croazia 8
MX - Messico 8
NO - Norvegia 8
PE - Perù 8
RS - Serbia 8
ID - Indonesia 7
LB - Libano 7
MY - Malesia 7
NZ - Nuova Zelanda 7
SN - Senegal 7
EG - Egitto 6
IL - Israele 6
TH - Thailandia 6
TN - Tunisia 6
AE - Emirati Arabi Uniti 5
BG - Bulgaria 4
IQ - Iraq 4
NG - Nigeria 4
KE - Kenya 3
ME - Montenegro 3
UY - Uruguay 3
VE - Venezuela 3
CU - Cuba 2
CY - Cipro 2
EC - Ecuador 2
GY - Guiana 2
JO - Giordania 2
LV - Lettonia 2
MK - Macedonia 2
PK - Pakistan 2
PS - Palestinian Territory 2
SD - Sudan 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
AL - Albania 1
BD - Bangladesh 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
IM - Isola di Man 1
KH - Cambogia 1
LT - Lituania 1
LU - Lussemburgo 1
MT - Malta 1
NI - Nicaragua 1
OM - Oman 1
PR - Porto Rico 1
QA - Qatar 1
UG - Uganda 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 27.437
Salva come PNG Salva come JPEG
Città #
Beijing 3.684
Chandler 2.190
Dublin 1.258
Houston 783
Jacksonville 673
Medford 466
Singapore 459
Villeurbanne 457
Fairfield 438
Ashburn 430
Ann Arbor 413
Princeton 397
Nyköping 393
Dearborn 390
Wilmington 346
Warsaw 245
Woodbridge 237
Milan 233
Toronto 217
Torino 200
Vienna 169
Seattle 148
Boardman 142
Verona 135
Dong Ket 131
Cambridge 130
Redwood City 129
Boston 123
Fremont 121
Pisa 90
Norwalk 75
Lachine 72
Santa Clara 70
Guangzhou 69
Turin 68
Falls Church 60
New York 59
Munich 55
Brussels 52
San Mateo 47
Detroit 45
Nanjing 42
Washington 41
Mountain View 36
Kunming 35
Rome 32
Tokyo 32
Hefei 30
Pune 29
Chicago 24
Chengdu 23
Hangzhou 23
Shanghai 23
Helsinki 20
Istanbul 20
Tappahannock 20
Seongnam 18
Seoul 18
Jinan 17
Los Angeles 17
Philadelphia 17
Buenos Aires 16
Paris 16
San Diego 16
Central 14
Frankfurt am Main 14
Phoenix 14
Redmond 14
Silver Spring 14
Taipei 14
Florence 13
Hong Kong 13
London 13
Nanchang 13
Portland 13
Moscow 12
Wuhan 12
Zhengzhou 12
Ankara 11
Brisbane 10
Hebei 10
San Francisco 10
Xian 10
Edinburgh 9
Ottawa 9
Polska 9
Rochester 9
São Paulo 9
Belgrade 8
Berlin 8
Bologna 8
Buffalo 8
Fuzhou 8
Newcastle upon Tyne 8
Padova 8
Shenyang 8
Sydney 8
Baotou 7
Barcelona 7
Düsseldorf 7
Totale 16.838
Salva come PNG Salva come JPEG
Nome #
Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. 406
Glucose metabolism in patients with subclinical Cushing's syndrome. 364
CUSHING'S SYNDROME IS ASSOCIATED WITH SLEEP ALTERATIONS DETECTED BY WRIST ACTIGRAPHY 336
BCLI POLYMORPHISM OF THE GLUCOCORTICOID RECEPTOR GENE IS ASSOCIATED WITH INCREASED OBESITY, IMPAIRED GLUCOSE TOLERANCE AND DYSLIPIDEMIA IN PATIENTS WITH ADDISON’S DISEASE 286
Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: A multicenter study 276
EARLY SURGERY AND SURVIVAL OF PATIENTS WITH ANAPLASTIC THYROID CARCINOMA: ANALYSIS OF A CASE SERIES REFERRED TO A SINGLE INSTITUTION BETWEEN 1999 - 2012. 252
ACUTE ADMINISTRATION OF ALPRAZOLAM, A BENZODIAZEPINE ACTIVATING GABA RECEPTORS, INHIBITS CORTISOL SECRETION IN PATIENTS WITH SUBCLINICAL BUT NOT OVERT CUSHING'S SYNDROME 249
Urinary cortisol and psychopathology in obese binge eating subjects. 241
Adjuvant mitotane treatment for adrenocortical carcinoma 240
Nephrotoxicity in advanced thyroid cancer treated with tyrosine kinase inhibitors: An update 240
Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center. 235
Enhanced oxidative stress and platelet activation in patients with Cushing's syndrome. 230
Effects of environmental pollutants on signaling pathways in rat pituitary GH3 adenoma cells 225
ACROSCORE: a new and simple tool for the diagnosis of acromegaly, a rare and underdiagnosed disease 209
MOLECULAR BACKGROUND AND GENOTYPE-PHENOTYPE CORRELATION IN APECED PATIENTS FROM CAMPANIA AND IN THEIR RELATIVES 179
IDENTIFICATION OF RISK CONDITIONS FOR THE DEVELOPMENT OF ADRENAL DISORDERS: HOW OPTIMIZED PUBMED SEARCH STRATEGIES MAKES THE DIFFERENCE 171
IMPROVEMENT OF ANTHROPOMETRIC AND METABOLIC PARAMETERS, AND QUALITY OF LIFE FOLLOWING TREATMENT WITH DUAL-RELEASE HYDROCORTISONE IN PATIENTS WITH ADDISON'S DISEASE 166
The endocrine response to ghrelin as a function of gender in humans in young and elderly subjects. 160
Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial 157
Endocrine Autoimmunity in Down's Syndrome 153
Are Evidence-Based Guidelines Reflected in Clinical Practice? An Analysis of Prospectively Collected Data of the Italian Thyroid Cancer Observatory 142
Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans. 139
Neuroendocrine effects of citalopram, a selective serotonine re-uptake inhibitor, during life span in humans 133
Effects of free fatty acids and acipimox, a lipolysis inhibitor, on the somatotroph responsiveness to GHRH in anorexia nervosa. 131
Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity. 127
Arginine reinstates the somatotrope responsiveness to intermittent growth hormone-releasing hormone administration in normal adults. 124
Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans. 122
The Mineralocorticoid Agonist Fludrocortisone Promotes Survival and Proliferation of Adult Hippocampal Progenitors 121
Acute administration of recombinant human growth hormone inhibits the somatotrope responsiveness to growth hormone-releasing hormone in childhood. 118
Interactions of galanin and arginine on growth hormone, prolactin, and insulin secretion in man. 117
Diagnosis of GH deficiency in adults. 113
Benzodiazepines and anterior pituitary function. 110
The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome. 110
ROLE OF MINERALOCORTICOID RECEPTORS ON HPA AXIS IN HUMANS 110
Human aging and the GH-IGF-I axis. 109
THE ACUTE EFFECT OF FLUDROCORTISONE ON BASAL AND HCRH-STIMULATED HYPOTHALAMIC-PITUITARY-ADRENAL (HPA) AXIS IN HUMANS 108
Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: comparison with insulin-induced hypoglycemia test. 107
Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects. 106
Activity of GH/IGF-I axis in patients with dilated cardiomyopathy 106
Ghrelin secretion is inhibited by glucose load and insulin-induced hypoglycaemia but unaffected by glucagon and arginine in humans 106
EVALUATION OF BASAL AND STIMULATED ACTIVITY OF THE HYPOTHALAMO-PITUITARY-ADRENAL (HPA) AXIS IN PATIENTS WITH PRIMARY HYPERALDOSTERONISM 106
GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism. 104
Acute clonidine administration potentiates spontaneous diurnal, but not nocturnal, growth hormone secretion in normal short children. 104
Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues 104
Repeated administration of growth hormone-releasing hormone with or without previous administration of pyridostigmine in insulin-dependent diabetes mellitus. 103
Adrenal responsiveness to high, low and very low ACTH 1-24 doses in obesity. 103
A neuroendocrinological approach to evidence an impairment of central cholinergic function in aging. 103
Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man. 103
Inhibition by salbutamol of GHRH-induced GH release in type 1 diabetes mellitus. 101
Arginine abolishes the inhibitory effect of glucose on the growth hormone response to growth hormone-releasing hormone in man. 101
Age-related growth hormone-releasing activity of growth hormone secretagogues in humans. 100
Evidence for involvement of endogenous somatostatin in the galanin-induced growth hormone secretion in children. 100
Pituitary lesions in breast cancer patients: A report of three cases. 100
Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. 99
[Neuroregulation of GH secretion in aging] 99
Pyridostigmine potentiates L-dopa- but not arginine- and galanin-induced growth hormone secretion in children. 99
A new test for the diagnosis of growth hormone deficiency due to primary pituitary impairment: combined administration of pyridostigmine and growth hormone-releasing hormone. 99
Benzene affects the response to octreotide treatment of growth hormone secreting pituitary adenoma cells 99
[Endocrine abnormalities in anorexia nervosa] 98
Effect of acute and prolonged mineralocorticoid receptor blockade on spontaneous and stimulated hypothalamus-pituitary-adrenal (HPA) axis in humans 98
EFFECTS OF CETRORELIX, A GnRH-RECEPTOR ANTAGONIST, ON GONADAL AXIS IN WOMEN WITH FUNCTIONAL HYPOTHALAMIC AMENORRHEA 98
The GH/IGF-I axis in obesity: influence of neuro-endocrine and metabolic factors. 97
Reproducibility of the growth hormone response to stimulation with growth hormone-releasing hormone plus arginine during lifespan. 97
DUAL-RELEASE HYDROCORTISONE IN ADDISON’S DISEASE-A REVIEW OF THE LITERATURE 97
Testing pituitary function in aging individuals 97
The IGF-I response to very low rhGH doses is preserved in human aging. 96
Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease. 95
Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging. 95
Enhanced adrenocorticotrophic hormone and cortisol responses to corticotrophin-releasing hormone in central idiopathic diabetes insipidus. 94
Comparison of the potentiating effect of pyridostigmine, arginine and propranolol on the GHRH-induced GH release in short children. 94
EFFECTS OF GNRH-RECEPTOR BLOCKADE ON GONADAL AXIS IN WOMEN WITH FUNCTIONAL HYPOTHALAMIC AMENORRHEA 94
Advanced glycation end products and chronic inflammation in adult survivors of childhood leukemia treated with hematopoietic stem cell transplantation 94
Growth hormone-releasing peptides. 93
Repetitive GHRH administration fails to increase the response to GHRH in obese subjects. Evidence for a somatotrope defect in obesity? 93
Do muscle fiber conduction slowing and decreased levels of circulating muscle proteins represent sensitive markers of steroid myopathy? A pilot study in Cushing’s disease 93
HYPERCORTISOLISM DUE TO CUSHING’S DISEASE IS ASSOCIATED TO DERANGED GHRELIN SECRETION AND ACTION 93
Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity. 92
Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. 92
GLUCOCORTICOID RECEPTOR POLYMORPHISMS AND METABOLIC-CARDIOVASCULAR PROFILE IN PATIENTS WITH ADDISON’S DISEASE UNDER REPLACEMENT THERAPY 92
GH replacement therapy and second neoplasms in adult survivors of childhood cancer: a retrospective study from a single institution. 92
Arginine but not pyridostigmine, a cholinesterase inhibitor, enhances the GHRH-induced GH rise in patients with anorexia nervosa. 91
Comparison of growth hormone-releasing effect of growth hormone-releasing hormone, clonidine and pyridostigmine in normal children and adolescents. GH-releasing effect of GHRH, clonidine and pyridostigmine. 91
Alprazolam (a benzodiazepine activating GABA receptor) reduces the neuroendocrine responses to insulin-induced hypoglycaemia in humans. 91
Neuroendocrine effects of subcutaneous sumatriptan in patients with migraine 91
Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans 90
Acute administration of pyridostigmine and clonidine has an additive stimulatory effect on GH release in normal children. 90
Orally active growth hormone secretagogues: state of the art and clinical perspectives. 88
Similarity of the nocturnal profile of serum melatonin at early puberty and early adulthood. 88
Metabolic modulation of the growth hormone-releasing activity of hexarelin in man. 88
The GH response to GHRH in normal adults is not affected by enalapril or furosemide while is blunted by digoxin. 87
Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration. 86
Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects. 86
Growth hormone secretion in Alzheimer's disease: studies with growth hormone-releasing hormone alone and combined with pyridostigmine or arginine. 85
GHRH and GH secretagogues: clinical perspectives and safety 85
Effects of direct and indirect acetylcholine receptor agonists on growth hormone secretion in humans. 85
Acetylcholine regulates ghrelin secretion in humans 85
Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging. 84
Effects of recombinant human insulin-like growth factor I administration on spontaneous and growth hormone (GH)-releasing hormone-stimulated GH secretion in anorexia nervosa. 84
Ageing, growth hormone and physical performance. 84
ACTIVITY OF GH/IGF-I AXIS IN PATIENTS WITH DILATED CARDIOMYOPATHY 84
Totale 12.788
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.102
article - articoli 0
book - libri 0
conference - conferenze 12.960
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.062
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.329 0 0 236 291 313 811 449 207 350 299 282 91
2020/20213.021 277 174 266 109 388 126 291 159 387 308 194 342
2021/20223.166 55 62 117 155 152 145 359 170 125 280 612 934
2022/20235.923 625 465 136 680 535 1.501 452 374 607 135 267 146
2023/20242.336 396 392 118 144 145 272 69 121 43 92 183 361
2024/2025602 75 468 59 0 0 0 0 0 0 0 0 0
Totale 28.421